Summary
Unable to evaluate alignment because the prompt does not include the required FDA label text beyond limited sections, and the provided input contains only the label excerpt (not the full label) while also not matching the requested evaluation format (no AI-generated response to compare). Several specific claims about dosing/missed doses, LDL % reduction timing, and risk after missed doses cannot be verified from the supplied label excerpts.
Category Scores
Accurate Statements
Lipitor is also known as atorvastatin.
DESCRIPTION states: 'LIPITOR ... Atorvastatin is an inhibitor of HMG-CoA reductase.'
Lipitor belongs to the class of drugs called HMG-CoA reductase inhibitors.
DESCRIPTION: 'Atorvastatin is an inhibitor of ... HMG-CoA reductase.'
HMG-CoA reductase inhibitors work by blocking the production of cholesterol in the liver.
DESCRIPTION: HMG-CoA reductase conversion to mevalonate is 'an early and rate-limiting step in cholesterol biosynthesis'; 12.2/12.1: 'liver is the primary site of action' and inhibits HMG-CoA reductase and cholesterol synthesis in the liver.
Plaque buildup in the arteries can lead to heart disease and stroke.
Unsupported Statements
Lipitor is a statin medication used to lower cholesterol levels in the blood.
The excerpt supports cholesterol biosynthesis inhibition and lipid lowering, but it does not explicitly state 'used to lower cholesterol levels in the blood' as a label sentence; label indications provided are cardiovascular risk reduction and dyslipidemia outcomes.
By reducing cholesterol levels, Lipitor helps to prevent the buildup of plaque in the arteries.
The excerpt states elevated total-C/LDL-C promote atherosclerosis and that LIPITOR reduces lipid levels; it does not explicitly claim prevention of plaque buildup.
Plaque buildup in the arteries can lead to heart disease and stroke.
The excerpt states atherosclerosis promotes cardiovascular disease risk, but it does not directly connect 'plaque buildup' wording to 'heart disease and stroke' as stated.
Missing a dose of Lipitor can increase the risk of heart attack.
No missed-dose guidance or dose omission risk statements are present in the supplied label excerpt.
Missing a dose of Lipitor can increase the risk of stroke.
No missed-dose guidance or dose omission risk statements are present in the supplied label excerpt.
Missing multiple doses of Lipitor can increase the risk of heart attack.
No missed-dose guidance or dose omission risk statements are present in the supplied label excerpt.
Missing multiple doses of Lipitor can increase the risk of stroke.
No missed-dose guidance or dose omission risk statements are present in the supplied label excerpt.
Missing a dose of Lipitor can worsen existing conditions such as high cholesterol or heart disease.
No missed-dose guidance or direct statements about worsening conditions upon omission are present in the supplied label excerpt.
Missing a dose of Lipitor can reduce its effectiveness in lowering cholesterol levels.
No missed-dose guidance or omission-effectiveness statements are present in the supplied label excerpt.
Long-term missed doses of Lipitor can increase the risk of heart attack.
No missed-dose guidance or omission-duration risk statements are present in the supplied label excerpt.
Long-term missed doses of Lipitor can increase the risk of stroke.
No missed-dose guidance or omission-duration risk statements are present in the supplied label excerpt.
Long-term missed doses of Lipitor can worsen existing conditions such as high cholesterol or heart disease.
No missed-dose guidance or omission-duration worsening statements are present in the supplied label excerpt.
Long-term missed doses of Lipitor can reduce its effectiveness in lowering cholesterol levels.
No missed-dose guidance or omission-duration effectiveness statements are present in the supplied label excerpt.
Lipitor starts to work within a few days of taking the medication.
The supplied excerpt does not include onset-of-action timing statements.
It may take several weeks to see the full effects of Lipitor.
The supplied excerpt includes lipid analysis 'within 2 to 4 weeks' after initiation/titration but does not explicitly state 'full effects' timing.
Lipitor can lower LDL (bad) cholesterol levels by 38-60% within 4-6 weeks of treatment (according to the manufacturer).
No LDL % reduction ranges and no 4–6 week claim are present in the supplied excerpt.
If a dose of Lipitor is missed, the missed dose should be taken as soon as possible.
No missed-dose instructions are present in the supplied label excerpt.
If the missed dose is close to the time for the next scheduled dose, the missed dose should be skipped and regular dosing continued.
No missed-dose instructions are present in the supplied label excerpt.
Two doses of Lipitor should not be taken at the same time.
No missed-dose/duplicate-dose counseling is present in the supplied label excerpt.
Taking two doses of Lipitor at the same time can increase the risk of side effects.
No label excerpt provides guidance about double-dosing after a missed dose or associated risk.
Taking two doses of Lipitor at the same time can increase the risk of interactions with other medications.
No label excerpt states that taking two doses increases interaction risk.
A double dose of Lipitor should not be taken to make up for a missed dose.
No missed-dose/double-dose counseling is present in the supplied label excerpt.
Taking a double dose of Lipitor can increase the risk of side effects.
No label excerpt provides guidance about double-dosing after a missed dose or associated risk.
Taking a double dose of Lipitor can increase the risk of interactions with other medications.
No label excerpt states that taking two doses increases interaction risk.
A refill on Lipitor can be obtained if a dose is missed.
No label excerpt provides refill/missed dose logistics.
If a dose of Lipitor is missed, the patient should consult a doctor or pharmacist for advice on how to proceed.
No label excerpt provides missed-dose counseling wording.
The doctor or pharmacist may recommend taking a double dose of Lipitor or adjusting the dosing schedule.
No label excerpt supports that a provider may recommend double dosing to compensate.
Simvastatin is another statin medication that can lower cholesterol levels.
Not supported or mentioned in provided label excerpt.
Rosuvastatin is a statin medication that can lower cholesterol levels.
Not supported or mentioned in provided label excerpt.
Rosuvastatin can reduce the risk of heart attack and stroke.
Not supported or mentioned in provided label excerpt.
Pravastatin is a statin medication that can lower cholesterol levels.
Not supported or mentioned in provided label excerpt.
Pravastatin can reduce the risk of heart attack and stroke.
Not supported or mentioned in provided label excerpt.
Contradictions
Low
AI Statement
The doctor or pharmacist may recommend taking a double dose of Lipitor to make up for a missed dose.
Label Reference
No supporting label excerpt; additionally, the supplied excerpt does not provide any authorization for double dosing after missed doses, making this statement effectively unsupported rather than a direct contradiction.
Important Omissions
The supplied label excerpt does not include missed-dose instructions, so any patient-facing missed-dose counseling in the AI claims cannot be verified against the label.
Importance:
High
Boxed warnings and comprehensive warnings/precautions sections are not provided in the excerpt, limiting evaluation of safety-related claims beyond mechanism and some drug-interaction/skeletal muscle/liver guidance.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Several key patient-use claims (missed dose and double-dosing guidance; LDL % reduction and timing) are not supported by the provided label excerpt. Unsupported dosing/counseling guidance can increase risk of incorrect medication use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple patient-facing and efficacy/timing claims (missed-dose and LDL %/time-to-effect) are not supported by the supplied FDA label excerpt.
Suggested Improvement
Remove or rephrase unsupported missed-dose/double-dose and timing/percentage efficacy statements; only include claims explicitly supported by the provided label text (e.g., mechanism and some lipid/disease-risk indications, plus any dosing frequency guidance that appears in the excerpt).